Østenstad B - Search Results

1

Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma.

Iversen PO, Negaard H, Østenstad B, Sandset PM, Kolset SO. Iversen PO, et al. Among authors: ostenstad b. Leuk Lymphoma. 2015;56(8):2479-81. doi: 10.3109/10428194.2013.803227. Epub 2013 Jun 12. Leuk Lymphoma. 2015. PMID: 23656198 No abstract available.

2

Angiogenesis and hemostasis in hematological neoplasias.

Negaard H, Dahm A, Sandset PM, Iversen PO, Østenstad B. Negaard H, et al. Among authors: ostenstad b. Curr Drug Targets. 2005 Sep;6(6):683-99. doi: 10.2174/1389450054863699. Curr Drug Targets. 2005. PMID: 16178801 Review.

3

Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM. Negaard HF, et al. Among authors: ostenstad b. J Clin Oncol. 2006 Jun 10;24(17):2683-4; author reply 2684. doi: 10.1200/JCO.2006.06.4345. J Clin Oncol. 2006. PMID: 16763285 No abstract available.

4

Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM. Negaard HF, et al. Among authors: ostenstad b. Thromb Haemost. 2008 Jun;99(6):1040-8. doi: 10.1160/TH07-09-0541. Thromb Haemost. 2008. PMID: 18521506

5

Increased acquired activated protein C resistance in unselected patients with hematological malignancies.

Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM. Negaard HF, et al. Among authors: ostenstad b. J Thromb Haemost. 2008 Sep;6(9):1482-7. doi: 10.1111/j.1538-7836.2008.03060.x. Epub 2008 Jun 28. J Thromb Haemost. 2008. PMID: 18573186 Free article.

6

Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.

Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO. Negaard HF, et al. Among authors: ostenstad b. Leukemia. 2009 Jan;23(1):162-9. doi: 10.1038/leu.2008.255. Epub 2008 Sep 18. Leukemia. 2009. PMID: 18800145

7

Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO. Negaard HF, et al. Among authors: ostenstad b. Leuk Lymphoma. 2009 Jun;50(6):998-1004. doi: 10.1080/10428190902889270. Leuk Lymphoma. 2009. PMID: 19373600

8

Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias.

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO. Negaard HF, et al. Among authors: ostenstad b. Leuk Lymphoma. 2011 Jun;52(6):1157-9. doi: 10.3109/10428194.2011.563886. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463121 No abstract available.

9

Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG). Kimby E, et al. Among authors: ostenstad b. Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686644 Clinical Trial.

10

Kiserud CE, Lockmer S, Baerug I, Dahl AA, Kimby E, Østenstad B. Kiserud CE, et al. Among authors: ostenstad b. Leuk Lymphoma. 2023 Feb;64(2):349-355. doi: 10.1080/10428194.2022.2142050. Epub 2022 Nov 7. Leuk Lymphoma. 2023. PMID: 36342349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page